Alisertib
Small Cell Lung Cancer (SCLC)
Key Facts
About Puma Biotechnology
Puma Biotechnology is a publicly traded biopharmaceutical company dedicated to enhancing cancer care through innovative therapeutics. The company successfully commercialized NERLYNX® (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer and is now expanding its pipeline via in-licensing, most notably with alisertib. Its strategic direction involves lifecycle management for its commercial asset while advancing mid-stage clinical programs in high-need oncology indications, positioning it for potential future growth.
View full company profileAbout Puma Biotechnology
Puma Biotechnology is a publicly traded biopharmaceutical company dedicated to enhancing cancer care through innovative therapeutics. The company successfully commercialized NERLYNX® (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer and is now expanding its pipeline via in-licensing, most notably with alisertib. Its strategic direction involves lifecycle management for its commercial asset while advancing mid-stage clinical programs in high-need oncology indications, positioning it for potential future growth.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer (SCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| Olvi-Vec | Genelux | Phase 2 |